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Abstract
Objective—To examine the survival benefit of multiple medical therapies in a large, community-
based population of validated myocardial infarction (MI) events.
Design—Retrospective observational cohort study.
Setting—Population-based sample of 30 986 definite or probable MIs in residents of four US
communities aged 35–74 years randomly sampled between 1987 and 2008 as part of the
Atherosclerosis Risk in Communities Surveillance Study.
Interventions—None.
Main outcome measures—All-cause mortality 30, 90 and 365 days after discharge.
Results—We used unadjusted and propensity score (PS) adjusted models to examine the
relationship between medical therapy use and mortality. In unadjusted models, each medication
and procedure was inversely associated with 30-day mortality. After PS adjustment, the crude
survival benefits were attenuated for all therapies except for intravenous tissue plasminogen
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activator therapy (IV-tPA) and stent use. After inclusion of other therapies received during the
event in regression models, risk ratio effect estimates (RR; (95% CI)) were attenuated for aspirin
(0.66; (0.58 to 0.76) to 0.91 (0.80 to 1.03)), non-aspirin antiplatelets (0.74; (0.59 to 0.92) to 0.92
(0.72 to 1.18)), IV-tPA (0.50; (0.41 to 0.62) to 0.65 (0.52 to 0.80)) and stents (0.53 (0.40 to 0.69)
to 0.68 (0.49 to 0.94)). Effect estimates remained stable for all other therapies and were similar for
90- and 365-day mortality endpoints.
Conclusions—We observed inverse associations between receipt of six medications and
procedures for MI and all-cause mortality at 30, 90 and 365 days after adjustment for PS. The
mortality benefits observed in this population-based setting are consistent with those reported in
clinical trials.
INTRODUCTION
Acute myocardial infarction (AMI) is the most common direct cause of mortality due to
coronary heart disease (CHD), and approximately 16% of patients who experience an AMI
will die within 1 year of hospitalisation.1 Death rates attributable to CHD have declined
since the 1960s,2–4 with nearly half of the decrease in CHD mortality attributable to medical
advancements.5 There is a rich literature of data from clinical trials and observational studies
reporting mortality benefits of medical therapy after myocardial infarction (MI). However,
clinical trials are often conducted in highly-selected patient populations and may not
represent what is observed in clinical practice.6–8 Observational studies provide a valuable
perspective into the therapeutic benefits of medications and procedures in community-based,
hospitalised settings and are increasingly using propensity score (PS) adjustment methods to
account for non-randomised study designs.9 However, few studies using PS to adjust for
confounding have examined modelling strategies to account for the use of multiple therapies
during a single hospitalised event.
In this study, we examined the association among 30-, 90- and 365-day all-cause mortality
and receipt of 11 medical therapies commonly used for treatment of hospitalised MI in a
population-based sample of the Atherosclerosis Risk in Communities (ARIC) Study
surveillance communities. We used four unique PS strategies to account for the non-
randomised study design and the effect of multiple medical therapies on all-cause mortality
after hospitalisation in a large, community-based population of validated MI events sampled
over 22 years.
METHODS
The design of the community surveillance component of the ARIC study has been
described.10 Briefly, it is a continuous retrospective surveillance study of hospitalised CHD
events with mortality follow-up designed to estimate trends in CHD incidence and mortality
using standardised criteria and methods in four US communities: Forsyth County, North
Carolina; Jackson, Mississippi; eight suburbs of Minneapolis, Minnesota; and Washington
County, Maryland. Eligible events included hospitalised fatal and non-fatal MI occurring
from 1987 to 2008 in 35–74-year-old residents of these communities. Details of the
sampling scheme for the community surveillance component in the ARIC study have been
previously reported.11 Trained abstractors investigate hospitalisations randomly sampled
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from annual discharge lists obtained from each hospital serving the four ARIC communities.
Events are sampled on age, gender, community of residence and International Classification
of Diseases (ICD-9) discharge codes, including 402, 410–414, 427, 428 and 518.4. Hospital
records for sampled cases are reviewed, and relevant clinical information is abstracted onto
standardised forms. Data items collected include presenting symptoms; timing of symptom
onset; history of MI, angina and other cardiovascular conditions; inhospital medications,
diagnostics and medical procedures; laboratory values for a number of relevant cardiac
biomarkers; and up to three sets of 12-lead ECG readings. Regular and ongoing inter-
abstractor agreement is assessed by evaluating concordance between data elements from a
sample of cases abstracted independently by two abstractors. Internal quality control
procedures at the ECG reading Centre are used to ensure reproducibility.
MI diagnostics
A computerised algorithm using evidence from ECG, history of chest pain and cardiac
biomarker levels (total creatine phosphokinase, creatine phosphokinase-myocardial band,
lactate dehydrogenase, troponin I and troponin T) was used to assign an MI diagnosis to
sampled hospitalised events (Definite MI, Probable MI, Suspected MI, no MI or
Unclassifiable). This analysis was restricted to events with a Definite or Probable MI
diagnosis. Any event with abnormal or equivocal biomarker levels was further classified as
ST- or non-ST segment elevation myocardial infarction (STEMI or NSTEMI) using pain
presentation and Minnesota-coded ECG data from the first, third or last ECG performed
during hospitalisation. Multiple hospitalisations occurring within 28 days were combined
and treated as one event.
Medical therapies
Medications and procedures were obtained from hospital pharmacy records and medical
record review during the abstraction process. Our analysis included data on seven
medication classes (ATC Codes): aspirin (A01AD05, B01AC06, N02BA01), β blockers
(C07), calcium channel blockers (C08), ACE inhibitors (ACEI; C09A, C09B), lipid-
lowering medications (C10), non-aspirin antiplatelet agents (B01AC) and heparin (B01AB);
and four reperfusion/revascularisation procedures: coronary artery bypass grafting (CABG),
thrombolytic therapy (intracoronary or intravenous streptokinase, urokinase, anistreplase,
anisoylated plasminogen streptokinase activator complex, or intravenous tissue plasminogen
activator (IV-tPA) reperfusion), coronary angioplasty (percutaneous coronary intervention;
PCI), and PCI with a stent. Each medication or procedure was classified as any receipt
during hospitalisation or at discharge (yes or no). Because several new therapies were
introduced during the study period, risk estimates for the following therapies were estimated
beginning with the first study year for which complete treatment information was collected
for all sampled events: heparin (beginning in 1992), ACEI (1992), non-aspirin antiplatelets
(1997), lipid-lowering medications (1999) and stent implantation (1999).
All-cause mortality
We analysed three outcomes of interest: 30-, 90- and 365-day all-cause mortality. Deaths
were confirmed by medical record review, state death records or linkage with the National
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Death Index. The 30-, 90- and 365-day classifications represent the intervals from hospital
admission date until date of death.
Exclusion criteria
From 1987 to 2008, 32 137 definite or probable MIs in patients aged 35–74 years were
sampled in the ARIC surveillance communities. We excluded patients whose race was not
classified as black or white (n=658) and due to insufficient sample sizes, black patients in
Minnesota or Washington County, Maryland (n=493). After these exclusions, the final
sample size for analysis was 30 985 definite or probable MI events.
Propensity score
PS represents the probability that a given subject will receive a treatment of interest, based
on that subject’s distribution of a selected set of covariates used to calculate the score. Given
a treatment Z (Z=1 if treated, 0 if untreated) and observed covariates X, the PS is given as
e(X)=prob(Z=1|X), or the probability that a patient with given values for covariates X will
be treated. The score is created by regressing receipt of each medical therapy in separate
logistic regression models on a set of covariates. The probability of receipt of treatment for
each subject, based on the covariates in the model, was retained and used as the PS for that
subject.
Candidate variables for inclusion in the PS were selected based on literature reviews,
clinical knowledge and directed acyclic graphs. We selected a standard set of clinical
covariates that are important risk factors for all-cause mortality: age (<45, 45–<55. 55–<65,
65+), male gender, race-centre cross classification ( Jackson blacks, Jackson whites, Forsyth
blacks, Forsyth whites, Minnesota whites and Washington whites), smoking status (ever vs
never), cardiogenic shock, congestive heart failure, cardiac arrest during hospitalisation,
history of diabetes, STEMI diagnosis, study year (1987–1991, 1992–1996, 1997–2001,
2002–2008), prior angioplasty and prior CABG.
Statistical analyses
We created medical therapy-specific PS models of the association between the standard set
of covariates and the receipt of each of 11 medical therapies. Because medications are rarely
received in isolation, we created three sets of PS to account for the effect of other
medications and procedures received during hospitalisation: (1) PS using the standard set of
clinical covariates demonstrated to be associated with survival after hospitalisation, without
consideration of receipt of other medications; (2) PS including all other medications and
procedures in addition to this standard set of covariates; and (3) PS with the standard set of
covariates and the dichotomised total number of other medical therapies received during
hospitalisation (<3 and ≥3). After creation of the scores, the model-specific distributions of
covariates within PS quintiles were compared, and model diagnostics were assessed. C-
statistic values for all models ranged from 0.63 to 0.85. Distributions of clinical covariates
were comparable between treated and untreated patients within score quintiles, as were
mean PS (data not shown). We excluded all observations in the non-overlap regions of the
PS distributions of the treated and untreated patients to ensure positivity and trimmed 5% of
the observations at each tail to eliminate potential bias introduced by subjects who were
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treated contrary to prediction.12 PS was then included in regression models as a set of binary
variables representing PS distribution quintiles.
All estimates presented are weighted to account for the ARIC surveillance sampling
scheme.10 We used a multivariable log-linear model with Poisson error distribution, which
produces a risk ratio (RR) effect estimate, to estimate the associations between receipt of
each medical therapy and 30-, 90- and 365-day all-cause mortality. To account for the
complex sampling scheme, all analyses were conducted using SAS-callable SUDAAN
(release V.9.2; Research Triangle Institute, Research Triangle Park, North Carolina, USA).
RESULTS
Table 1 shows selected characteristics for 30 986 MI patients, overall and by mortality strata
(all-cause mortality within 30, 90 and 365 days of discharge). The unadjusted risk of death
within 30 days of hospitalisation for definite or probable MI was 7.5%; within 90 days,
8.6%; and within 365 days, 10.0%. Compared with the entire population of hospitalised MI
patients, those who died within 30 days of hospitalisation were older, less likely to be male
subjects, and more likely to be black subjects, have a history of stroke, have diabetes, arrive
by emergency medical services (EMS) and be classified as NSTEMI. Similar patterns were
observed in patients who died within 90 days of hospitalisation and those who died within
365 days of hospitalisation. Patients who died within 30, 90 or 365 days of hospitalisation
were less likely to have a prehospital delay time of less than 2 h. Of all deaths that occurred
within 30 days of hospitalisation, a higher proportion were observed in earlier time periods
(33.4% in 1987–1991) than in the later time periods (19.5% in 2002–2008). A similar
pattern was observed for deaths within 90 days (34.3% in 1987–1991 vs 32.5% in 2002–
2008) and for deaths within 365 days (32.0% in 1987–1991 vs 23.5% in 2002–2008).
Figure 1 shows the distribution of total medications prescribed per event by study year
category. In this figure, events were grouped into intervals of 5, 6 or 7 years to promote
stability in CI estimates. The mean total number of medications per hospitalisation increased
from 1.77 (95% CI 1.73 to 1.81) in the first study year interval to 4.76 (95% CI 4.69 to 4.83)
in the fourth interval. Over time, the normalised distribution of total number of medications
per hospitalisation shifted to the right, indicating a higher number of medications per
hospitalisation in recent years compared with earlier years.
Table 2 presents the total percentage of patients receiving each medical therapy of interest
over the study period (%; 95% CI) and the unadjusted risk of mortality at 30, 90 and 365
days following hospitalisation in patients who received each medical therapy. Aspirin was
the most commonly used medication throughout the study period, followed by β blockers,
heparin and lipid-lowering medications. Angioplasty was the most commonly used
procedure, with over half of angioplasty patients receiving a stent. Crude mortality risks
were lower for patients receiving any of the medications or procedures of interest than in the
overall population.
Table 3 presents risk ratios estimating the association between receipt of each medical
therapy and 30-day all-cause mortality by PS regression strategy. The unadjusted estimates
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(Model A. Unadjusted) indicate reductions in all-cause mortality associated with each
medication and procedure. After inclusion of the PS in regression models (Model B. PS
Only), the crude mortality effects were attenuated for all therapies except for IV-tPA and
stent use. After inclusion of the PS in regression models (Model C. PS+all other medical
therapies), effect estimates (RR; (95% CI)) were substantially attenuated for aspirin and
moderately attenuated for non-aspirin antiplatelets, IV-tPA and stents. Model D shows
results from a model including PS created from the standard set of covariates plus a variable
representing dichotomised number of total medications per hospitalised event (<3, ≥3).
Estimates from this model were similar to those from Model C, with the exception of stents
(0.51 (0.42 to 0.63)) and IV-tPA (0.56 (0.41 to 0.75)), both of which showed increased
mortality benefit in Model D compared with Model C. Effect estimates from this model
were moderately attenuated for all medical therapies except for angioplasty and IV-tPA,
which were comparable with the estimates obtained from Model D.
Because mortality benefits associated with pharmaceutical therapy may differ among
patients undergoing reperfusion, we ran two sets of sensitivity analyses of medication use
and 30-day mortality in IV-tPA and PCI patients, respectively. For patients receiving PCI,
we found similar mortality benefits for all medications except for calcium channel blockers,
which were no longer protective. For IV-tPA, we found larger mortality benefits associated
with the use of aspirin, β blockers and non-aspirin antiplatelets; the protective effect of
calcium-channel blockers also disappeared in this subgroup.
Tables 4 and 5 present the association between receipt of each medical therapy and 90- and
365-day mortality (respectively) using the same strategies used to model 30-day mortality.
Similar patterns in mortality by model strategy were observed for both 90-and 365-day
endpoints. To examine the stability of effect estimates over time, we ran a sensitivity
analysis limiting our dataset to events occurring from 2002 to 2008. Estimates from this
analysis were similar to those obtained from the entire set of events.
DISCUSSION
To our knowledge, this is the first study to examine how the mortality benefits of evidence-
based therapies change when accounting for the use of multiple medications in a population-
based sample of validated MI events. In this study, we observed inverse associations
between medication use and all-cause mortality at 30, 90 and 365 days after hospitalised MI
for β blockers, calcium channel blockers, aspirin, lipid-lowering medications, non-aspirin
antiplatelets and ACEI after adjustment for PS created from a standard set of clinical
covariates. These inverse associations were attenuated but remained significant after adding
all medical therapies to the PS regression model, with the exception of non-aspirin
antiplatelets, which were no longer protective after inclusion of all therapies. Similar
patterns were observed when examining 90- and 365-day mortality endpoints. Our results
are similar in magnitude and direction to those observed in a number of large-scale clinical
trials for β blockers,13, 14 aspirin,15 calcium channel blockers,16 ACEI,17, 18 heparin19 and
lipid-lowering medications.20 As has been observed in number of clinical trials, the
mortality benefit of non-aspirin antiplatelets was attenuated substantially after accounting
for the use of other medications.21, 22
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Inverse associations between receipt of inhospital procedures and 30-day mortality were
observed with the inclusion of PS from a standard set of clinical covariates and remained
stable for all four procedure groups after inclusion of variables representing number and
type of other medical therapies in regression models. Observed mortality benefits in this
study are similar to those reported in clinical trials of PCI,23, 24 PCI with stent,23, 25 IV-tPA
and CABG.26
The consistency of our study results with those of clinical trials further strengthens existing
evidence for real-world efficacy of commonly used MI therapies. This study is unique in its
analysis of all-cause mortality and medication receipt in a community-based, observational
setting. Studies of causal inference of medication use and survival in cardiovascular disease
are often structured as randomised clinical trials, widely considered the gold standard for
causal inference in the study of treatment effects.27 However, clinical trials have stringent
inclusion and exclusion criteria, and evidence from several studies indicates that clinical trial
populations may not represent how AMI patients are treated in routine clinical practice.6–8
In the current study, we used rigorous methodology and careful covariate selection to
minimise bias typically found in observational analyses.
Because clinical trials usually focus on the effect of a single therapy in isolation, the benefit
of common cardiovascular therapies in the context of multiple medications is often unclear.
To address the issue of whether therapeutic benefits persist in the setting of multiple
medications, we created three sets of PS including the number and type of other medical
therapies administered during hospitalisation. Results from these models suggest mortality
benefits at 30, 90 and 365 days for β blockers, aspirin, lipid-lowering medications and ACEI
even after accounting for the presence of other medications during creation of PS. Similar
associations for all mortality endpoints were found when all variables used to create the PS
were included in a standard loglinear regression model.
Strengths
The ARIC community surveillance study offers a number of advantages in the study of
medical therapy for acute MI and all-cause mortality after discharge. The study population is
a large, racially and geographically diverse community-based sample with validated MI
diagnostics. As clinical data are collected from randomly sampled hospitalised events,
selection bias is minimised relative to typical observational cohort studies, where the
patients who elect not to participate are often sicker and poorer than the rest of the patient
population. Because the ARIC study monitors hospitalised events over a 22-year period, we
were able to observe associations between medical therapy and mortality over a period of
changing clinical practice landscape. Additionally, because of the large number of validated
events in this population, we had adequate statistical power to detect medical therapy
benefits for shorter-term timepoints. Finally, the rich clinical data collected by the ARIC
study, including presence of comorbidities, procedure history, inhospital complications and
STEMI/NSTEMI classification, allowed us to account for the presence of potentially
important confounders, an integral component to observational analyses of medication use
and postdischarge mortality.
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Because the ARIC community surveillance study is observational in nature, assignment of
patients to medical therapies of interest is not randomised. While we tried to account for
major known confounders through the use of PS, unmeasured confounding may exist.
Additionally, the retrospective nature of the study limited our ability to account for the
potential confounding effect of variables not collected as part of the study protocol. For
patients discharged on aspirin, we did not have information on dosage or whether aspirin
was prescribed for pain therapy or antiplatelet therapy. Finally, we were unable to assess
prescription filling patterns or modifications to medication regimens after discharge.
As the proportion of MI patients receiving multiple medications during hospitalisation
continues to increase, so does the importance of accounting for the effect of all therapies
when analysing the survival benefit of a particular medication or revascularisation
procedure. Results from well-designed clinical trials and observational studies assessing
mortality reductions associated with cardiovascular medications and procedures have
contributed to substantial improvements in the quality of care for hospitalised AMI over the
past decades. Future research should assess the benefit of emerging therapies from a
comprehensive perspective of the course of inhospital treatment for acute MI.
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Normalised density plot of total medications per hospitalisation for definite/probable
myocardial infarction by study year category: the Atherosclerosis Risk in Communities
Surveillance Study (1987–2008). *Density indicates the likelihood that the random
variable(total number of medications per hospitalised event) will take on a given value from
0–8. Higher density reflects higher probability of observing the corresponding number of
medications. This figure is only reproduced in colour in the online version.
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Table 1
Baseline patient and event characteristics of definite and probable MI patients overall and by primary
outcomes of interest in the ARIC Community Surveillance Study, 1987–2008
Variable
All patients
N=30 986* % (SE)
Death within 30 days†
N=2337 % (SE)
Death within 90 days
N=2669 % (SE)
Death within 365 days
N=3106 % (SE)
Age in years, mean (SD) 60.4 (0.09) 64.5 (0.28) 64.2 (0.29) 64.0 (0.28)
Male gender 65.7 (0.42) 58.4 (1.53) 58.1 (1.51) 58.8 (1.4)
Race-centre classification
 Forsyth black 12.3 (0.33) 13.0 (1.14) 13.6 (1.09) 16.9 (1.16)
 Forsyth white 10.6 (0.30) 11.6 (1.14) 12.0 (1.14) 11.1 (1.03)
 Jackson black 10.6 (0.28) 15.1 (1.14) 15.6 (1.12) 16.7 (1.10)
 Jackson white 28.7 (0.42) 8.4 (1.45) 28.1 (1.43) 26.3 (1.30)
 Minnesota whites 20.4 (0.36) 7.1 (1.19) 15.9 (1.12) 15.0 (1.03)
 Washington whites 17.5 (0.30) 7.3 (0.93) 14.8 (0.87) 14.0 (0.81)
Comorbidities
 Prior MI 32.6 (0.44) 34.8 (1.47) 35.2 (1.42) 36.6 (1.38)
 Hypertension 63.6 (0.44) 64.4 (1.53) 64.1 (1.52) 65.9 (1.42)
 Diabetes 25.0 (0.42) 26.8 (1.28) 26.2 (1.22) 28.0 (1.22)
 Stroke 9.3 (0.28) 17.2 (1.23) 17.7 (1.15) 17.4 (1.1)
Length of stay in days, mean (SD) 7.9 (0.09) 7.9 (0.26) 10.1 (0.37) 10.3 (0.37)
EMS transport 42.1 (0.47) 52.5 (1.59) 52.9 (1.55) 52.2 (1.47)
Prehospital delay‡
 <2 h 27.4 (0.40) 20.6 (1.26) 20.0 (1.18) 19.5 (1.08)
 Unknown 11.7 (0.39) 27.0 (0.60) 27.4 (1.75) 25.7 (1.61)
Event classification§
 STEMI 19.7 (0.32) 21.0 (1.13) 20.1 (1.05) 18.8 (0.96)
 NSTEMI 65.5 (0.44) 69.8 (1.42) 69.5 (1.40) 69.7 (1.34)
Study year
 1987–1991 24.3 (0.36) 33.4 (1.47) 34.2 (1.45) 32.0 (1.35)
 1992–1996 25.0 (0.38) 25.0 (1.37) 23.9 (1.30) 23.2 (1.24)
 1997–2001 23.8 (0.36) 22.2 (1.24) 21.4 (1.16) 21.3 (1.10)
 2002–2008 27.0 (0.42) 19.5 (1.26) 20.5 (1.29) 23.5 (1.29)
Receipt of reperfusion¶ 46.2 (0.45) 20.7 (1.03) 20.3 (1.00) 20.0 (0.95)
Total number of medications received
 0 4.5 (0.25) 3.1 (0.23) 3.0 (0.23) 3.0 (0.23)
 1 9.8 (0.31) 8.9 (0.32) 8.7 (0.32) 8.5 (0.32)
 2 17.0 (0.36) 17.0 (0.37) 16.9 (0.38) 16.9 (0.38)
 3 21.2 (0.36) 21.6 (0.38) 21.7 (0.38) 21.8 (0.38)
 4+ 47.5 (0.44) 49.5 (0.46) 49.7 (0.46) 49.8 (0.47)
*
Weighted number of definite or probable MI events.
†
All-cause mortality from the first day of the hospitalised event.
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‡
Prehospital delay was defined as the interval from the earliest symptom onset time to hospital arrival time.
§
STEMI defined as ST-elevation at any site on either the first or last ECG.
¶
Reperfusion included thrombolysis, PCI with or without stent, and CABG.
ARIC, Atherosclerosis Risk in Communities; CABG, coronary artery bypass grafting; MI, myocardial infarction; NSTEMI, non-ST segment
elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.
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